Need:
A leading biotech company had grown its asset portfolio into multiple indications and needed a way enable its management and board directors to stay on top new threats and opportunities across multiple markets.
Assignment
MSC’s long standing relationship with the client as deal-making support made MSC a natural choice to deliver insights from CI surveillance. Together with the client, a format was designed that enabled efficient screening of relevant deals, competitor updates and new opportunities as they emerged. The assignment led to a monthly delivery that ensures that the client keeps up to date for discussions with shareholders, strategic partners and investors.
